Civica Rx CEO Martin VanTrieste says Civica’s members are experiencing fewer shortages because of strategies used by the company.
Second of three parts
Drug shortages aren’t in the headlines as much as they were when Civica Rx was founded in 2018, CEO Martin VanTrieste says that lack of appearance may be deceiving.
“You don’t see it as much in the news because we’re focused on something else right now, called the pandemic,” VanTrieste said in an interview this week with Managed Healthcare Executive.
But in this segment of a wide-ranging interview conducted earlier this week, VanTrieste also says that Civic Rx’s members — which now include 50 healthcare systems comprising roughly 1,500 hospitals — are experiencing fewer shortages because Civica’s strategies have alleviated the problem. The strategies include strategic stockpiling and redundant suppliers.
Moreover, earlier this year, Civica announced that it was constructing a manufacturing facility in Petersburg, Virginia.
In another part of the interview, VanTrieste said it is currently supplying 60 drugs to hospitals is aiming to increase that number to 100 within the first five years of the company’s existence, or 2023,
In this segment, VanTrieste also discussed the three tiers of Civica’s membership program. “Partnering members” on the lowest tier pay $300 per licensed hospital bad “so it’s very affordable to a community hospital,” VanTrieste said. In some cases, the organization may waive the one-time fee. Hospitals also pay Civica for the drugs they buy.
Conversations With Perry and Friends: Paul Fronstin, Ph.D.
May 9th 2025Perry Cohen, Pharm.D., a longtime member of the Managed Healthcare Executive editorial advisory board, is host of the Conversations with Perry and Friends podcast. In this episode, his guest is Paul Fronstin, Ph.D., director of health benefits research at the Employee Benefit Research Institute.
Listen
Conversations With Perry and Friends
April 14th 2025Perry Cohen, Pharm.D., a longtime member of the Managed Healthcare Executive editorial advisory board, is host of the Conversations with Perry and Friends podcast. His guest this episode is John Baackes, the former CEO of L.A. Care Health Plan.
Listen
FDA Accepts NDA for Zoliflodacin, Potentially First Gonorrhea Antibiotic in Decades
June 13th 2025The FDA has accepted a New Drug Application for zoliflodacin, a first-in-class oral antibiotic for treating uncomplicated gonorrhea, offering a potential new option amid rising antibiotic resistance.
Read More